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We investigated the role of ICAM-3 in DC-SIGN-mediated human immunodeficiency virus (HIV) infection of CD4+ T cells. Our results
demonstrate that ICAM-3 does not appear to play a role in DC-SIGN-mediated infection of CD4+ T cells as virus is transmitted equally to ICAM-3+
or ICAM-3− Jurkat T cells. However, HIV-1 replication is enhanced in ICAM-3− cells, suggesting that ICAM-3 may limit HIV-1 replication. Similar
results were obtained when SIV replication was examined in ICAM-3+ and ICAM-3− CEMx174 cells. Furthermore, while ICAM-3 has been
proposed to play a co-stimulatory role in T cell activation, DC-SIGN expression on antigen presenting cells did not enhance antigen-dependent
activation of T cells. Together, these data indicate that while ICAM-3 may influence HIV-1 replication, it does so independent of DC-SIGN-
mediated virus transmission or activation of CD4+ T cells.
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Myeloid dendritic cells (DCs) are among the first cells to
encounter human immunodeficiency virus type 1 (HIV-1) upon
its transmission across the mucosal epithelium (Pope and Haase,
2003). DCs can transport virus to lymph nodes where a robust
replication in CD4+ T cells is initiated (Hu et al., 2000; Spira
et al., 1996). In vitro, DCs form an infection synapse with CD4+
T cells that facilitates viral transmission (Cameron et al., 1992;
McDonald et al., 2003; Weissman et al., 1995). Within the
synapse, DCs present HIV-1 to the CD4/coreceptor complex for
infection of the T cells (Arrighi et al., 2004; Cameron et al.,
1992; Pope et al., 1994). Similar to an immunological synapse
between T cells and antigen presenting B cells (Grakoui et al.,
1999), the synapse between DCs and T cells is formed through
rapid relocalization of various cell surface molecules to the sites
of cell–cell contact in the absence of classical antigen pre-
sentation (de la Fuente et al., 2005; Revy et al., 2001). The DC/T
cell infection synapse not only includes the HIV-1 virion but also⁎ Corresponding author. Fax: +1 713 798 4435.
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doi:10.1016/j.virol.2007.03.017the viral receptor (CD4) and co-receptor (CCR5/CXCR4) as
well as the adhesion molecule LFA-1 (McDonald et al., 2003).
Additionally, the DC-specific C-type lectin, DC-SIGN (DC-
Specific ICAM-3 Grabbing Non-integrin), has been shown to
be present in the infection synapse (Arrighi et al., 2004).
While it has been demonstrated that DC-SIGN plays a role in
virion capture and transmission to CD4+ target cells
(Geijtenbeek et al., 2000a; Pohlmann et al., 2001; Yu Kimata
et al., 2002), how it enhances HIV-1 infection is not completely
defined.
DC-SIGN is a type II transmembrane lectin binding protein
that is expressed on DCs and macrophages (Curtis et al., 1992;
Geijtenbeek et al., 2000b; Granelli-Piperno et al., 2005; Satomi
et al., 2005). Current studies have demonstrated that the cal-
cium-dependent carbohydrate recognition domain of DC-SIGN
binds high mannose residues in the HIV-1 envelope glycopro-
tein (Env SU) in order to capture virions (Biggins et al., 2004;
Curtis et al., 1992; Geijtenbeek et al., 2000a; Mitchell et al.,
2001; Yu Kimata et al., 2002). Captured virions are then trans-
mitted to CD4+ T cells for an infection in trans (Biggins et al.,
2004; Geijtenbeek et al., 2000a; Mitchell et al., 2001). Within
the context of this in trans infection of the T cells, it has been
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tivity and the ability to evade host immune surveillance through
various potential mechanisms. First, virions internalized by DC-
SIGN may be protected from degradation (Blauvelt et al., 1997;
Kwon et al., 2002; Nobile et al., 2005; Sol-Foulon et al., 2002)
and possibly neutralizing antibodies (Ganesh et al., 2004).
Second, it has been suggested that internalization of virions with
subsequent recycling to the DC surface promotes infectivity
(Kwon et al., 2002; Zhang et al., 1999). Alternately, infection of
DCs may lead to de novo replication of the virus for trans-
mission to CD4+ T cells (Burleigh et al., 2006; Nobile et al.,
2005).
DC-SIGN is proposed to also interact transiently with
intercellular adhesion molecule-3 (ICAM-3) on the surface of T
cells during the initial formation of an immunological synapse
(van Kooyk and Geijtenbeek, 2002). ICAM-3 is a member of
the immunoglobulin superfamily and contains five immuno-
globulin-like domains (de Fougerolles et al., 1993; de Fou-
gerolles and Springer, 1992; Vazeux et al., 1992). It is
constitutively expressed on the surface of resting T cells and
can function as a co-stimulatory molecule during T cell acti-
vation (Berney et al., 1999; de Fougerolles et al., 1994; Fawcett
et al., 1992; van Kooyk and Geijtenbeek, 2002). ICAM-3 also
facilitates the initial contact between antigen presenting cells
and T cells (Montoya et al., 2002). The cellular ligands LFA-1
and DC-SIGN are recognized via domains one and two,
respectively (Holness et al.,1995; Geijtenbeek et al., 2002;
Jimenez et al., 2005). Early studies have suggested that DC-
SIGN binds to ICAM-3 in a similar fashion to the interaction
with HIV-1 Env SU, and that this interaction may be important
for T cell activation, as antibodies to DC-SIGN have been
reported to inhibit T cell activation (Geijtenbeek et al., 2000b).
Additionally, although it has been demonstrated that HIV-1 can
infect resting T cells in vivo (Zhang et al., 1999, 2004), infection
occurs much more efficiently in activated T cells (Eckstein
et al., 2001; Scales et al., 2001; Stevenson et al., 1990; Zack
et al., 1990). Thus, DC-SIGN may stimulate HIV-1 infection
of CD4+ T cells through an ICAM-3-dependent mechanism.
In the current study, we examined the significance of ICAM-
3 during both HIV-1 infection and activation of CD4+ T cells in
the presence of DC-SIGN. Our data indicate that while DC-
SIGN enhances HIV-1 infection of CD4+ T cells in trans, virion
transmission is not facilitated by the presence of ICAM-3.
Furthermore, DC-SIGN did not enhance T cell activation.
Interestingly, ICAM-3 appears to influence viral replication
independent of DC-SIGN. Our data suggest that DC-SIGN
functions as an antigen capture factor that is capable of trans-
mitting virus to CD4+ Tcells, but that it does not play a role in T
cell activation. Instead, the effects of ICAM-3 on viral repli-
cation may occur independent of DC-SIGN.
Results
Selection of ICAM-3 negative Jurkat cell line
To examine the importance of DC-SIGN–ICAM-3 interac-
tions for HIV-1 infection, an ICAM-3 negative T cell line wasgenerated by sterile cell sorting for the ICAM-3 negative popu-
lation. Jurkat cells were chosen because they have functional
ICAM-3 costimulatory activity, capable of enhancing HIV-1
expression (Barat et al. 2004; Hayflick et al., 1997). The sorted
cells were then expanded and examined by FACS to confirm the
absence of ICAM-3 (ICAM-3−) expression as compared to wild
type Jurkat cells (ICAM-3+) (Fig. 1A). In addition, the cell
surface expression of various T cell markers was assessed by
flow cytometry. Expression levels of HIV receptor (CD4) and
co-receptor (CXCR4) on the ICAM-3− Jurkat cells were com-
parable to those observed on wild type Jurkat cells as indicated
by similar mean fluorescence intensities (MFIs). Furthermore,
the MFI of cells stained with anti-CD3 and anti-CD28 antibo-
dies was the same for both cell lines (Fig. 1A).
In order to confirm that the ICAM-3− Jurkat cells are still
permissive for HIV-1 infection, a single cycle infection of
ICAM-3− Jurkat cells was performed with an HIVΔenv-
luciferase reporter virus pseudotyped with a CXCR4-tropic HIV
envelope. No difference in the level of luciferase activity was
observed between the wild type and ICAM-3− Jurkat cells
infected with equal amounts of virus (100–300 ng p24) (Fig.
1B). When infections were allowed to proceed for 7 days, there
were still similar levels of luciferase activity in the ICAM-3
positive and negative Jurkat cells (data not shown). These data
indicate that the ICAM-3− Jurkat cells remain permissive for
HIV-1 infection and that ICAM-3 may not be required for in-
fection of T cells.
DC-SIGN-mediated transmission of HIV is independent of
ICAM-3 expression
To examine whether ICAM-3 expression on target T cells is
necessary for DC-SIGN-mediated infection of CD4+ T cells, we
performed virion capture and transfer assays with ICAM-3+ or
ICAM-3− Jurkat cells and Raji cells expressing DC-SIGN. In
order to accomplish this, Raji cells stably expressing pig-tailed
macaque DC-SIGN (Fig. 2A) or wild type Raji cells were
separately incubated with increasing amounts of an HIV-luci-
ferase virus for several hours. After washing away unbound
virus, the cells were co-cultured with either ICAM-3− or ICAM-
3+ Jurkat cells. On the third day post-infection, a luciferase
assay was performed in order to assess virus infection. For DC-
SIGN-mediated capture and transfer of virus to either ICAM-3
positive or negative Jurkat cells, there was a similar 7-fold
increase in luciferase activity as compared to cultures contain-
ing DC-SIGN− Raji cells, which showed low level transmission
activity (Fig. 2B). This indicates that there was no difference in
DC-SIGN-dependent infection of the ICAM-3 positive or nega-
tive Jurkat cells. Similar results were observed when the co-
culture was allowed to proceed for 7 days (data not shown).
Thus, ICAM-3 does not appear to influence DC-SIGN-depen-
dent HIV-1 infection of CD4+ T cells.
To examine the possibility that activation of the target cells
may be required in order to observe a difference in virus infection
of ICAM-3− Jurkat cells as compared to the wild type cells, we
performed the DC-SIGN-mediated virus capture and transfer
assay as described above in the presence of the superantigen,
Fig. 1. Selection and infection of ICAM-3 negative Jurkat cell line. (A) Phenotype of wild type and ICAM-3− Jurkat cells. The wild type Jurkat cells (ICAM-3+) and
mutant (ICAM-3−) cells were examined for surface expression of ICAM-3, CD3, CD28, CD4, and CXCR4 (closed curves). Isotype control antibodies are represented
by open curves. The mean fluorescence intensity (MFI) of the stained cells is indicated on each histogram. (B) HIV-1 infection of wild type and ICAM-3 negative
Jurkat cells. Jurkat cells were incubated with an HIV-luciferase virus pseudotyped with a CXCR4-tropic HIV-1 envelope or left untreated for 3 h. On the third day post-
infection, cells were harvested and virus production was analyzed by measuring luciferase activity in the infected cell lysates. Mock treated cells were used for
background controls. The amount of pseudotyped virus added is shown as nanograms (ng) of p24. Relative luciferase activity±standard error of the mean (SEM) is
shown.
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luciferase activity in either ICAM-3− or ICAM-3+ Jurkat cells
when superantigen was added to the co-cultures as compared to
those co-cultures in which superantigen was absent, the
differences were not significant. More importantly, the level
of luciferase activity between the ICAM-3+ and ICAM-3− cells
in the presence of superantigen was similar. These results
indicate that DC-SIGN-mediated HIV-1 infection occurs inde-
pendently of ICAM-3 in the context of superantigen-mediated T
cell activation.
To confirm the results obtained with the DC-SIGN-ex-
pressing Raji cell line, we performed a similar virus capture and
transfer assay using human monocyte-derived DCs. As in the
experiments with DC-SIGN-expressing Raji cells, ICAM-3+
and ICAM-3− Jurkat cells showed similar levels of infection
when virus was presented by human monocyted-derived DCs,
further suggesting that ICAM-3 does not play a role in DC-
mediated infection of T cells (Fig. 2D). While there was an
apparent 2-fold increase in transmission by DCs at the higher
dose of virus, the difference is neither significant nor repeatable.Taken together, these data suggest that ICAM-3 is not important
for the initial infection of CD4+ T cells, whether by direct in-
fection or DC-SIGN-dependent transmission.
HIV and SIV replication are enhanced in the absence of
ICAM-3
To determine whether ICAM-3 may have an effect on
viral replication independent of DC-SIGN, we infected the
ICAM-3− or ICAM-3+ Jurkat cells with replication competent
HIV-1NL4-3. Interestingly, we observed about a 4-fold greater
level of virus production from ICAM-3− Jurkat cells as
compared to the wild type ICAM-3+ Jurkat cells at 14 days
post-infection (Fig. 3). This increase is significant (p<0.05,
Student's t-test), suggesting that ICAM-3 may play a role in
limiting HIV-1 replication during a spreading infection. The
difference in virus production levels is not due to differences in
cell viability as there is no significant difference in viable cell
number between infected ICAM-3 positive and negative Jurkat
cells (data not shown).
Fig. 2. DC-SIGN-mediated transmission of HIV-1 to ICAM-3 positive and negative Jurkat cells. (A) Pig-tailed macaque DC-SIGN-expressing Raji cells were created
via retroviral transduction. DC-SIGN expression was confirmed through FACS analysis by using an anti-DC-SIGN monoclonal antibody (filled curves) or isotype
control antibody (open curves). (B) Capture and transmission of HIV from DC-SIGN+ Raji cells to ICAM-3− Jurkat cells. DC-SIGN+ Raji cells were incubated with a
pseudotyped HIV-luciferase virus for 2 h, washed, and then co-cultured with target cells. On the third day post-infection virus production was analyzed by measuring
luciferase activity in target cells. (C) Capture and transmission of HIV-1 from DC-SIGN+ Raji cells to ICAM-3− Jurkat cells in the presence of superantigen. DC-SIGN-
mediated virus capture and transfer assay was performed as described above. Co-cultures were maintained in the presence or absence of staphylococcal enterotoxin D
(SED). (D) Capture and transmission of HIV-1 from primary human dendritic cells to ICAM-3− Jurkat cell line. A DC-SIGN-mediated virus capture and transfer assay
was performed as described above except that human monocyte-derived dendritic cells were substituted for DC-SIGN+ Raji cells. All of the experiments were
performed in triplicate and the data are representative of at least two independent experiments. Mock treated cells were used for background direct virus infection.
Relative luciferase activity±SEM is shown.
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cation, we examined whether it would also limit SIV replication.
For these studies, we generated an ICAM-3 negative CEMx174
cell line, since these cells are permissive for SIV replication. AnFig. 3. HIV-1 replication is enhanced in the absence of ICAM-3. ICAM-3− or
ICAM-3+ Jurkat cells were infected with HIV-1NL4-3 at a low multiplicity of
infection (MOI). At various times during a 2-week period post-infection
supernatants were collected and virus production was measured by p24
antigen capture ELISA. Experiments were performed in triplicate, and the data
are representative of three independent experiments. The average levels of
p24gag±SEM are shown.ICAM-3 negative population of cells (ICAM-3−) was obtained
through cell sorting (Fig. 4A). In addition, the cell surface ex-
pression of the HIV receptor (CD4) on the ICAM-3− CEMx174
cells was assessed by flow cytometry and found to be com-
parable to ICAM-3+ parental CEMx174 cells as demonstrated
by the similar MFIs. When these cells were infected with the
SIV molecular clone, SIVmne170, we observed a highly sig-
nificant (p<0.001) 7-fold increase in viral production from
ICAM-3− CEMx174 cells as compared to the wild type ICAM-
3+ CEMx174 cells at days 10 and 14 post-infection (Fig. 4B).
Additionally, after 7 days of infection, cell viability in the
SIVmne170-infected ICAM-3− CEMx174 cells was decreased
by approximately 10-fold more than that in the ICAM-3+ wild
type cells, as a result of greater cell killing (Fig. 4C). Similar
observations were made using two other molecular variants of
SIVmne clones. These data further indicate that while ICAM-3
is not involved in DC-SIGN-dependent viral transmission, it
may limit viral replication.
DC-SIGN does not modulate T cell activation
Because it has previously been suggested that DC-SIGNmay
initiate contact between APCs and T cells, we also examined
Fig. 4. Selection and infection of ICAM-3 negative CEMx174 cells. (A) Phe-
notype of wild type and ICAM-3− CEMx174 cells. The wild type CEMx174
cells (ICAM-3+) and mutant (ICAM-3−) cells were examined for surface ex-
pression of ICAM-3 and CD4 (closed curves). Isotype control antibodies are
represented by open curves. The mean fluorescence intensity (MFI) of the
stained cells is indicated on each histogram. (B) SIV infection of wild type and
ICAM-3− CEMx174 cells. (C) Extrapolated viable cell number of wild type and
ICAM-3− CEMx174 cells. CEMx174 cells were infected with SIVmne170 at a
low MOI. At various times during a 2-week time period post-infection super-
natants were collected and virus production was measured using an SIV p27
antigen capture ELISA. The average levels of p27gag±SEM are shown.
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absence of DC-SIGN in Jurkat:Raji co-cultures. Using the DC-
SIGN-expressing Raji cell line or wild type Raji cells, weevaluated the influence of DC-SIGN on T cell activation in the
context of superantigen presentation. We found that treatment of
Jurkat cells with anti-CD3 and anti-CD28 antibodies resulted in
a 35-fold induction of IL-2 over unstimulated Jurkat cells (Fig.
5A CD3/CD28) and upregulation of the early activation marker
CD69 from 26% to 90% of Jurkat cells (Fig. 5B CD3/CD28).
Similarly, when Jurkat cells were incubated with either DC-
SIGN+ or DC-SIGN− Raji cells in the presence of SED, IL-2
was induced 10-fold (Fig. 5A DC-SIGN−/+ +SED) and CD69
was upregulated to 78% of cells (Fig. 5B DC-SIGN−/DC-
SIGN++SED), albeit to a lesser extent than the anti-CD3/anti-
CD28 antibody activation control. When we compared the
amount of activation marker upregulation between cultures
with DC-SIGN+ Raji cells to DC-SIGN− Raji cells, we found
no significant difference in IL-2 concentration (Fig. 5A DC-
SIGN−+SED vs. DC-SIGN++SED). Likewise, a comparison
of CD69 expression between DC-SIGN-expressing and wild
type Raji cell cocultures revealed no significant difference (Fig.
5B DC-SIGN−+SED vs. DC-SIGN++SED).
To further investigate DC-SIGN-mediated activation of T
cells we tested whether DC-SIGN+ Raji cells would be better
able to activate Jurkat cells than DC-SIGN− Raji cells at higher
Jurkat to Raji cell ratios. Jurkat cells were mixed with the ap-
propriate number of either DC-SIGN+ or wild type Raji cells at
ratios of 20:1, 10:1, 2:1 or 1:1 Jurkat to Raji cells. No significant
difference was observed in CD69 upregulation (data not shown)
or in IL-2 concentration (Fig. 5C), regardless of the T cell:Raji
ratio. Taken together, these data suggest that DC-SIGN may not
play a role in altering antigen-dependent T cell activation.
Soluble DC-SIGN does not co-stimulate T cells
Alternative splicing of DC-SIGN transcripts is predicted to
result in the production of a soluble form of DC-SIGN (Mum-
midi et al., 2001). Thus, to further characterize effects of DC-
SIGN on T cell activation, we tested the ability of a recombinant
soluble DC-SIGN (sDC-SIGN) molecule to co-stimulate T cells
treated with anti-CD3 antibodies. sDC-SIGN was generated
with a Drosophila expression system and purified from culture
supernatants via affinity purification (Fig. 6A). We performed
immunoprecipitation experiments with our sDC-SIGN con-
struct to confirm its ability to bind ICAM-3, but were unable to
detect this interaction (data not shown). Given the high disso-
ciation constant for interactions between recombinant DC-
SIGN and ICAM-3 (KD=4.6 μM) (Satomi et al., 2005), these
results were not entirely unexpected. Therefore, we assessed
sDC-SIGN functionality by examining its ability to inhibit
virion capture by cell-associated DC-SIGN.We found that sDC-
SIGN competitively inhibited binding of HIV-1 virions to DC-
SIGN-expressing cells by 75% (Fig. 6B), similar to inhibition
by EGTA and mannan, other known inhibitors of DC-SIGN
virion capture activity.
To determine if purified sDC-SIGN could stimulate T cells,
we incubated Jurkat cells with combinations of anti-CD3, anti-
CD28 antibodies, and sDC-SIGN. The results indicate that anti-
CD3 antibody alone is able to induce IL-2 production, albeit at a
lower level (13 pg/mL of IL-2 with 1 μg of anti-CD3) than that
Fig. 5. DC-SIGN does not modulate T cell activation. (A) IL-2 concentration in
supernatants after activation. (B) CD69 surface expression on Jurkat cells. Jurkat
cells were either cultured alone and unstimulated, co-cultured with either DC-
SIGN+ or DC-SIGN− Raji cells with or without Staphylococcal enterotoxin D
(SED), or cultured alone and treated with anti-CD3 and anti-CD28 antibodies.
The average IL-2 levels±SEM are shown. (C) Activation of Jurkat cells in the
presence of different amounts of DC-SIGN+ Raji cells. Jurkat cells were co-
cultured with either DC-SIGN+ or DC-SIGN− Raji cells and SED at the
indicated ratios. After 24 h, culture supernatants were examined for IL-2
concentration by ELISA. The average IL-2 levels±SEM are shown.
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ment (Fig. 6C). When cells were stimulated with the anti-CD3
antibody in the presence of sDC-SIGN, either adhered to the
plate or added to the culture supernatant, no significant increase
in IL-2 concentration was measured even with levels of sDC-
SIGN reaching 6 μg per well (Fig. 6C and data not shown). To
demonstrate that ICAM-3 signaling is functional in the Jurkat
cell line, an activating ICAM-3 antibody (ICR1.1) was used in
conjunction with the anti-CD3 antibody to stimulate Jurkat
cells. While anti-ICAM-3/anti-CD3 antibody treatment is not as
effective (250 pg/mL) as anti-CD3/anti-CD28 antibody co-
stimulation (540 pg/mL), anti-ICAM-3/anti-CD3 antibody
treatment was able to increase IL-2 concentration over that of
anti-CD3 antibody alone (107 pg/mL) and, more importantly,
over that seen with anti-CD3 antibody/sDC-SIGN treatment(62 pg/mL adhered sDC-SIGN, 110 pg/mL supernatant sDC-
SIGN) (Fig. 6D). Statistical analysis was performed and the
increase in IL-2 production by the anti-CD3/anti-ICAM-3 treat-
ment was found to be highly significant (p-value <0.001) over
that of anti-CD3/sDC-SIGN co-stimulation. These results de-
monstrate that while ICAM-3 signaling is intact in the Jurkat
cells, sDC-SIGN was unable to use this signaling pathway to
enhance IL-2 production. Together, these data suggest that DC-
SIGN is unable to function as a co-stimulatory molecule in
either the context of the immunological synapse formed by Raji
cell presentation of superantigen or when potent signaling
through the TCR is present.
To further demonstrate that the interaction between DC-
SIGN and ICAM-3 does not play a role in T cell activation, we
incubated ICAM-3+/− Jurkat/DC-SIGN+/− Raji cell co-cultures
with SED and measured IL-2 concentration. As shown in Fig. 7,
there was no difference in the IL-2 production from co-cultures
regardless of the status of ICAM-3 or DC-SIGN. These results
further confirm that the binding of DC-SIGN to ICAM-3 does
not affect IL-2 production from Jurkat cells.
Discussion
DC-SIGN is a pathogen capture factor expressed on the
surfaces of immature dendritic cells and macrophages that
facilitates HIV-1 and SIV transmission to CD4+ T cells (Wu and
KewalRamani, 2006). However, the mechanism by which DC-
SIGN enhances infection is not well understood, and its
involvement in DC-mediated enhancement of infection remains
controversial. Initial studies showed that DC-SIGN is able to
both bind HIV-1 and facilitate transmission of virions from
dendritic cells to target cells in vitro. However, recent studies
indicate that DC-SIGN's primary function in this process may
not be virion capture but transmission of virions to CD4+ T cells
and formation of an infection synapse (Arrighi et al., 2004;
Geijtenbeek et al., 2000a; Mitchell et al., 2001). Furthermore,
other studies have suggested that DC-mediated enhancement of
HIV-1 and SIV infection may occur by mechanisms indepen-
dent of DC-SIGN (Boggiano et al., 2007; Gummuluru et al.,
2003; Wu et al., 2002b). Because DC-SIGN interacts with
ICAM-3, an additional proposed function is that DC-SIGN
increases HIV-1 infection by promoting interactions with CD4+
T cells and activation through the cellular ligand, ICAM-3
(Geijtenbeek et al., 2000b). Here, we evaluated the importance
of DC-SIGN–ICAM-3 interactions for HIV-1 infection and T
cell activation. The data indicate that DC-SIGN acts as a capture
factor that enhances infection in trans, but not as a costi-
mulatory molecule that modulates the activation status of
CD4+ T cells or increases infection via contact with ICAM-3.
Interestingly, ICAM-3 appears to modulate HIV-1 and SIV
replication independent of DC-SIGN.
We demonstrate that ICAM-3 does not play a functional role
in the transmission of HIV-1 from DC-SIGN expressing cells to
CD4+ T cells using ICAM-3 positive and negative Jurkat T
cells as targets. Similar results were obtained whether HIV-1
was transmitted by either DC-SIGN+ Raji cells or primary
human DCs or if viral infection was performed during antigen-
Fig. 6. Soluble DC-SIGN does not co-stimulate T cells. (A) Expression of sDC-SIGN. Conditioned supernatants from S2 cells stably expressing sDC-SIGN were
collected and subjected to SDS-12% polyacrlyamide gel electrophoresis (PAGE). Awestern blot was performed and the His-tagged protein was detected by enhanced
chemiluminescence. Cells were either left untreated (−) or induced to express DC-SIGN with copper sulfate (+). (B) sDC-SIGN inhibition of virion capture. DC-SIGN
expressing 293T cells were incubated with indicated inhibitors for 20 min. The cells were then incubated with SIVmne170 for 2 h. Cells were washed, lysed, and the
amount of virus remaining bound to the cell surface was determined by antigen capture ELISA. Mock treated cells were used for background controls. Virus captured
in the presence of each inhibitor is shown relative to untreated cells after correcting for background binding±SEM. (C) Co-stimulation assay. Jurkat cells were added to
wells coated with indicated amounts of anti-CD3 antibody alone (▪), anti-CD3 antibody+1 μg sDC-SIGN ( ), coated with anti-CD3 antibody only and 1 μg sDC-
SIGN added to culture medium ( ), or coated with anti-CD3+1 μg anti-CD28 antibodies (□). After 24 h culture supernatants were examined for IL-2 concentration
by ELISA. (D) ICAM-3 activation. Jurkat cells were added to wells left untreated or coated with 1 μg/well each of anti-CD3 antibody, anti-CD3 antibody and sDC-
SIGN, anti-CD3 antibody only with sDC-SIGN added to culture supernatant, anti-CD3, and anti-ICAM-3 (ICR1.1) antibodies, or anti-CD3 and anti-CD28 antibodies.
After 24 h, IL-2 concentration was measured in supernatants by ELISA. The average IL-2 levels±SEM are shown. Two-tailed Student's t-test was performed:
p<0.001.
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Wu et al. who demonstrated that DC-SIGN binding to ICAM-3
does not play a role in DC-SIGN-mediated virus transmission
by using blocking antibodies and soluble ICAM-3, as well as
engineered expression of ICAM-3 on GHOST/R5 target cells
(Wu et al., 2002a). Furthermore, because we did not observe
differences in virus transmission between ICAM-3 positive and
negative Jurkat cells, the data suggest that if DC-SIGN is
important for the formation of an infection synapse, it may be
via a mechanism other than binding to ICAM-3.
In earlier studies, it had been demonstrated that DC-SIGN
could induce T cell activation and proliferation in DC-T cell
mixed lymphocyte reactions (Geijtenbeek et al., 2000b).
Therefore, we evaluated the effects of DC-SIGN on Jurkat T
cell activation in the context of superantigen presentation byRaji cells with or without DC-SIGN. The presence of DC-
SIGN did not increase the induction of IL-2 or CD69 on target
Jurkat T cells, suggesting that DC-SIGN was unable to actuate
any signaling event that leads to any modulation in T cell
activation. This was probably not likely due to an inability of
DC-SIGN to bind ICAM-3, as we and others have shown that
DC-SIGN is capable of binding to ICAM-3 (Biggins et al.,
2004; Geijtenbeek et al., 2000b, 2002). Furthermore, we show
that co-stimulation through ICAM-3 with an activating anti-
ICAM-3 antibody can induce IL-2 expression in Jurkat T cells,
indicating that the ICAM-3 co-stimulatory pathway is func-
tional in the Jurkat clone used in these experiments. Consistent
with the cell-associated DC-SIGN experiments, we also found
that a soluble DC-SIGN molecule could not costimulate Jurkat
cells. Together, these data suggest that DC-SIGN is unable to
Fig. 7. IL-2 production is sustained despite loss of ICAM-3-DC-SIGN
interaction. Wild type or ICAM-3− Jurkat cells were cocultured with either
wild type or DC-SIGN+ Raji cells in the presence or absence of Staphylococcal
enterotoxin D (SED). Alternately, Jurkat cells cultured alone were treated with
anti-CD3 and anti-CD28 antibodies or left untreated. After 24 h, IL-2 supernatant
levels were analyzed by ELISA. The average IL-2 levels±SEM are shown.
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in agreement with recent studies that used anti-DC-SIGN
blocking antibodies to show that DC-SIGN is not involved in
the induction of T cell proliferation (Granelli-Piperno et al.,
2005; Real et al., 2004). Additionally, domain I of ICAM-3 has
been shown to be the activation domain, but biochemical
studies suggest that DC-SIGN may interact with high mannose
carbohydrate residues linked to domain II (Jimenez et al.,
2005), which is not involved in transducing activation signals
in T cells (Bossy et al., 1995; Hernandez-Caselles et al., 1993).
Thus, DC-SIGN–ICAM-3 interactions may not result in
activation events that enhance HIV-1 infection of T cells.
Furthermore, that we did not observe greater infection of
ICAM-3+ Jurkat cells compared to ICAM-3− cells when HIV-1
is transmitted by DC-SIGN in either the presence or absence of
superantigen is further confirmation that DC-SIGN–mediated
co-stimulation via ICAM-3 does not play a role in transmission
of HIV-1.
A potential caveat to these experiments is that they were
performed with Jurkat T cells as targets for infection. Jurkat T
cells were chosen because it has been shown that they can
transduce costimulatory activation signals via ICAM-3 and
because HIV-1 gene expression is enhanced in Jurkat cells after
costimulation via CD3 and ICAM-3 with anti-CD3 and anti-
ICAM-3 monoclonal antibodies (Barat et al., 2004; Hayflick
et al., 1997; Montoya et al., 2002). Nevertheless, further studies
with primary resting CD4+ T cells could provide additional
insight. Secondly, we primarily used macaque DC-SIGN for
our studies, which may differ from human DC-SIGN in
binding to human ICAM-3. However, this is not likely as we
and others have previously shown that human ICAM-3 binds
to both macaque DC-SIGN and human DC-SIGN, and that the
interaction is likely mediated by recognition of carbohydrate
residues in ICAM-3 (Baribaud et al., 2001; Yu Kimata et al.,
2002; Biggins et al., 2004).
One intriguing observation of this study is that both HIV-1
and SIV show greater replication kinetics in CD4+ lymphocytecell lines that do not express ICAM-3. The data suggest that
ICAM-3 may negatively regulate T cell activities involved in
viral replication. How this may occur is unclear. Furthermore,
the signaling mechanisms of ICAM-3 remain poorly character-
ized. There is suggestion that ICAM-3 expression may play a
negative regulatory role in Tcell activation responses (Green and
Thompson, 1996). Given the importance of activation events
for HIV-1 infection and replication, this type of activity may
also diminish HIV-1 and SIV replication in CD4+ T cells.
Furthermore, because luciferase expression was similar in
single-round infections of the ICAM-3+ and ICAM-3− Jurkat
cells using the Env pseudotyped HIV-luc vector, events in the
viral life cycle leading to viral gene expression probably do
not account for the differences in viral replication in the
presence and absence of ICAM-3. Further confirmation of our
results by siRNA knockdown of ICAM-3 expression in
primary CD4+ T cells may provide additional insight into the
effects of ICAM-3 on viral replication.
In summary, DC-SIGN-mediated transmission of HIV-1 to
CD4+ T cells occurs independent of the interaction between
DC-SIGN and ICAM-3. Additionally, while ICAM-3 is known
to play a co-stimulatory role in T cell activation and enhance-
ment of HIV-1 transcription, DC-SIGN does not enhance anti-
gen-dependent or independent activation of T cells. Therefore,
we conclude that DC-SIGN–ICAM-3 interactions do not lead to
enhanced activation or HIV-1 infection of CD4+ T cells. Thus,
the data are consistent with a model in which HIV-1 subverts the
pathogen capture function of DC-SIGN for enhanced transmis-
sion to CD4+ T cells in context of an infection synapse. Finally,
independent of DC-SIGN, ICAM-3 may modulate the extent of
HIV-1 replication.
Materials and methods
Cell lines and viruses
CEMx174, Jurkat, and Raji cells were cultured in RPMI
1640 medium containing 10% heat inactivated fetal bovine
serum (FBS), 100 U of penicillin per mL, 100 μg of strep-
tomycin per mL, and 2 mM glutamine (RPMI complete). DC-
SIGN+ Raji cells were maintained as described below. The
293T cell line and PT67 packaging cell line were cultured in
Dulbecco's modified Eagle's medium (DMEM) supplemented
with 10% FBS, 2 mM glutamine, 100 U of penicillin per mL,
and 100 μg of streptomycin per mL (DMEM complete). Human
monocyte-derived DCs were generated from peripheral blood
mononuclear cells (PBMCs) as previously described (Yu
Kimata et al., 2002). Briefly, CD14+ monocytes were isolated
via anti-CD14 microbeads and miniMACS system according to
the manufacturer's instructions (Miltenyi Biotech, Auburn,
CA). The CD14+ monocytes were then washed with RPMI
complete media and cultured with 1000 U/mL each of granu-
locyte-macrophage colony-stimulating factor (GM-CSF) and
Interleukin-4 (IL-4) (R&D Systems, Minneapolis, MN) in
RPMI complete media for 7 days to generate dendritic cells. By
FACS analysis greater than 95% of these cells express DC-
SIGN (data not shown).
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ing 293T cells with both the plasmid expressing the CXCR4-
tropic HIV envelope (pHxB2-env) and the plasmid containing
the HIV-luciferase proviral genome (HIV-luc, a gift from N.
Landau). The cells were washed with phosphate buffered saline
(PBS) 24 h later, and then cultured in fresh DMEM complete
medium. The following day, supernatants were collected, passed
through 0.22 μm syringe filters, and saved at −80 °C until use
for infection experiments. The amount of virus was deter-
mined by p24 antigen capture ELISA (Coulter-Immunotech,
Miami, FL).
Replication competent HIV-1NL4-3 and SIVmne170 virus
stocks were generated by transiently transfecting 293T cells
with plasmid proviral clones, washing with PBS 24 h later, and
then culturing in fresh DMEM complete medium. The follo-
wing day, supernatants were collected, passed through 0.22 μm
syringe filters, and saved at −80 °C until used for infection
experiments. The amount of HIV p24gag antigen or SIV p27gag
antigen was quantified using a commercial ELISA (Immuno-
tech-Coulter, Miami, FL).
Selection of ICAM-3− cells
Approximately 30×106 Jurkat or CEMx174 cells were
stained with 1 μg FITC-conjugated anti-ICAM-3 antibody
(R&D Systems, Minneapolis, MN) for 30 min at 4 °C in a
FACS staining buffer (PBS supplemented with 10% FBS)
without sodium azide. The cells were then sterile sorted using
a Beckman-Coulter Ultra high speed, high pressure cell sorting
machine for the cell population negative for ICAM-3
expression. The ICAM-3− cells were collected in RPMI
complete media and allowed to expand. The absence of
ICAM-3 expression was confirmed by staining the sorted cells
in a FACS staining buffer containing 0.1% sodium azide for
30 min at 4 °C with the same anti-ICAM-3 antibody. After
washing with PBS, the cells were resuspended in 1%
paraformaldehyde and analyzed with a Beckman Coulter
EPICS XL-MCL. The Jurkat cells were then subjected to a
second sterile sort in order to obtain a homogeneous
population of ICAM-3− cells while the CEMx174 cells
underwent two subsequent sterile sorts. These cells maintained
a stable ICAM-3− phenotype during 6 months of continuous
culturing.
Transduction and selection of DC-SIGN expressing Raji cells
The cDNA encoding pig-tail macaque DC-SIGN was inser-
ted into the pLNCX retroviral vector (Clontech) at the HpaI
and ClaI restriction sites. We previously showed that macaque
DC-SIGN is structurally and functionally similar to human
DC-SIGN (Baribaud et al., 2001; Yu Kimata et al., 2002). The
PT67 retroviral packaging cell line was then transiently
transfected via FuGene lipid carrier (Roche, Indianapolis, IN)
with the DC-SIGN/pLNCX vector. Forty-eight hours post-
transfection the virus was harvested and Raji cells were spin-
inoculated in the presence of 0.8 μg/mL polybrene at 32 °C for
1 h. The cells were then incubated overnight at 32 °C andresuspended in fresh media. After an additional 48 h, the cells
were placed under 1 mg/mL G418 selection media. Viable cells
were stained with an anti-DC-SIGN monoclonal antibody
(8C1; Yu Kimata et al., 2002) and a FITC-conjugated goat anti-
mouse secondary antibody (Dako Corp, Carpinteria, CA). The
cells were then examined by FACS analysis as described above
for expression of DC-SIGN (Fig. 2). As compared to the
parental cells, greater than 98% of the transduced cells
expressed DC-SIGN. The cells were also subjected to sterile
sorting, as described above, in order to isolate a population of
Raji cells that expressed high levels of DC-SIGN on the cell
surface.
Infection of cell lines
ICAM-3+ or ICAM-3− Jurkat cells (2×105) were incubated
with varying amounts of a HIV-luciferase virus pseudotyped
with a CXCR4 tropic HIV envelope or left untreated for 3 h at
37 °C in a 96-well round bottom plate. The cells were then
washed vigorously 3 times with RPMI complete media. Follo-
wing the last wash, the cells were resuspended in 150 μL RPMI
complete media and transferred to a 24-well plate where the
final volume was 2 mL RPMI complete media. On day 3 or 7
post-infection, cells were harvested and a luciferase assay
(Roche, Indianapolis, IN) was performed according to manu-
facturer instructions with a tube luminometer (Berthold Detec-
tion Systems).
HIV-1 capture and transmission assays were performed as
previously described (Yu Kimata et al., 2002). Briefly, either
1×105 DC-SIGN+ or DC-SIGN− Raji cells were incubated with
varying amounts of HIV-luciferase virus pseudotyped with a
CXCR4 tropic HIV-1 envelope or left untreated for 2 h. The
cells were then washed 3 times and co-cultured with either
2×105 ICAM-3+ or ICAM-3− Jurkat cells. On day 3 post-
infection, cells were harvested and a luciferase assay (Roche)
was performed according to the manufacturer's instructions.
Similar experiments were performed with cells harvested 7 days
post-infection. For capture and transmission assays that include
Staphylococcol enterotoxin D (SED; Toxin Technology, Inc.,
Sarasota, FL), the cells were co-cultured in the presence of
100 ng SED. For capture and transmission assays that include
human DCs, a similar protocol was followed, substituting 1×
105 human DCs for 1×105 Raji cells.
Direct infection with replication competent HIV-1NL4-3 or
SIVmne170 was performed by incubating ICAM-3− or ICAM-
3+ Jurkat or CEMx174 cells (2×105) with the appropriate
virus (1ng p24gag antigen HIV NL4-3 or 1ng p27gag antigen
SIVmne170, respectively) or DMEM complete media in a 96
well U-bottom plate for 2–4 h at 37 °C. The cells were then
washed vigorously 3 times with RPMI complete media. Follo-
wing the last wash, the cells were resuspended in 150 μL RPMI
complete media and transferred to a 24-well plate where the
final volume was 2 mL RPMI complete media. At various time
points during a 2 week period supernatants were collected from
each well and analyzed by antigen capture ELISA (Immuno-
tech-Coulter, Miami, FL). Cell viability was determined by
trypan blue dye exclusion.
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In order to create a soluble DC-SIGN (sDC-SIGN) molecule
the extracellular neck and CRD domains were amplified by PCR
and inserted into a Drosophila expression vector, pMTBiP/V5-
His, which would allow a his-tagged DC-SIGN molecule to be
secreted upon induction in Drosophila S2 cells (Invitrogen,
Carlsbad, CA). S2 cells stably carrying the expression vector
were produced by co-transfecting the expression plasmid along
with a plasmid encoding for the blasticidin selectable marker.
Forty-eight hours post-transfection the cells were selected in
Drosophila growth media and blasticidin (25 μg/mL). To
produce the soluble secreted DC-SIGN protein, expression of
the sDC-SIGN was induced with copper sulfate. Twenty-four to
forty-eight hours post-induction conditioned supernatants were
collected and expression of his-tagged sDC-SIGN was con-
firmed by Western Blot. The His-tagged protein was detected
with a 1:5000 dilution of a horseradish peroxidase coupled anti-
His antibody by enhanced chemiluminescence. sDC-SIGN
protein was purified away from the conditioned supernatant
through affinity purification with a nickel chelating column and
varying concentrations of imidazol according to the manufac-
turer's instructions (Invitrogen). In order to remove the imidazol,
the sDC-SIGN protein was dialyzed against a native purification
buffer (250 nM NaPO4, 2.5 M NaCl) that does not contain
imidazole. Expression of the sDC-SIGN protein was confirmed
by western blot and quantified by the Micro BCA Protein Assay
Kit (Pierce, Rockford, IL).
sDC-SIGN capture inhibition assay
293T cells were transiently transfected with either a pig-
tailed macaque (pt) DC-SIGN expression vector or pcDNA3
vector without insert using the FuGene 6 reagent (Roche).
Twenty-four hours post-transfection the cells were replated in a
96 well U-bottom plate at a concentration of 1×105 cells per
well in 100 μL. The following day the cells were pretreated
with purified sDC-SIGN, 20 μg/mL mannan, 5 mM EGTA, or
DMEM complete media for 20 min at 37 °C. The cells were
then incubated with SIVmne170 (5 ng p27gag antigen) or
DMEM complete for 2 h at 37 °C, washed vigorously 2 times
with DMEM complete media, and one time with PBS. After the
last wash the cells were resuspended in PBS and transferred to a
fresh 96 well U-bottom plate that contains triton-X100 for cell
lysis. The resulting lysate was examined by antigen capture
ELISA to determine the amount of virus bound to the cell
surface.
Co-stimulation assays
24-well plates were coated with antibodies in a volume of
0.5 mL PBS for 3 h at 37 °C. The plates were then washed twice
with PBS, blocked with 1% bovine serum albumin in PBS for
30 min and washed a final time with PBS. Wells used for
stimulation controls were coated with 1 μg each of anti-CD3
and anti-CD28 antibodies (BD Biosciences, San Diego, CA;
Zhou et al., 2001). For the ICAM-3 co-stimulation control,wells were coated with 1 μg each of the anti-CD3 antibody and
anti-ICAM-3 antibody, ICR1.1 (Joel Hayflick, ICOS; Hayflick
et al., 1997). For experiments with soluble DC-SIGN (sDC-
SIGN), wells were coated with 1 μg of the anti-CD3 antibody
and sDC-SIGN was added to the culture supernatant or adhered
to the plate concurrently with the anti-CD3 antibody. Jurkat
(106) cells were then added to each well in a 1 mL volume of
RPMI complete media and incubated for 24 h at 37 °C. The
cells were then pelleted by centrifugation and supernatants were
harvested for use in an IL-2 ELISA, which was performed
according to the manufacturer's instructions (R&D Systems).
The pelleted cells were stained with anti-CD20-PE and anti-
CD69-PECy5 antibodies (BD Biosciences) in FACS staining
buffer for 30 min on ice. The cells were fixed with 1% para-
formaldehyde in PBS and FACS analysis was performed.
SED superantigen stimulation
Staphylococcal enterotoxin D (SED) is a superantigen that is
able to bind the Vβ8 chain found on the Jurkat E61 T cell and
induce activation (Fraser et al., 1992; Kimata et al., 1994;
Marrack and Kappler, 1990). Jurkat cells and either DC-SIGN−
or DC-SIGN+ Raji cells were mixed at different ratios in a
volume of 2 mL RPMI complete media in the presence of
100 ng of Staphylococcal enterotoxin D (SED; Toxin Tech-
nology, Inc., Sarasota, FL). DC-SIGN+ Raji cells were washed
once with PBS and resuspended in RPMI complete media prior
to use in co-cultures. After 24 h the cells were then pelleted by
centrifugation and the supernatants were harvested for use in an
IL-2 ELISA while the pelleted cells were analyzed by flow
cytometry as described above.
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